Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 10/20 | 0.45 |
| ▸ | AURKA | O14965 | 10/20 | 0.45 |
| ▸ | AURKC | Q9UQB9 | 5/20 | 0.45 |
| ▸ | PLK4 | O00444 | 3/20 | 0.45 |
| ▸ | SRC | P12931 | 2/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.44 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.44 |
| ▸ | STK25 | O00506 | 1/20 | 0.44 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | GAK | O14976 | 1/20 | 0.44 |
| ▸ | MUSK | O15146 | 1/20 | 0.44 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.44 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.44 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.44 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3043627 | 1.00 | AURKB (0.45) | AURKBAURKAAURKCPLK4SRC | |
| SCHEMBL3037858 | 0.89 | AURKB (0.45) | AURKBAURKAAURKCPLK4SRC | |
| SCHEMBL3042680 | 0.88 | AURKB (0.55) | AURKBAURKAAURKCPLK4SRC | |
| SCHEMBL3044546 | 0.83 | AURKB (0.60) | AURKBAURKAAURKCSRCABL1 | |
| SCHEMBL13220901 | 0.80 | AURKB (0.56) | AURKBAURKAAURKCPLK4SRC | |
| SCHEMBL3042700 | 0.79 | AURKA (0.45) | AURKBAURKAAURKCSRCGSK3B | |
| SCHEMBL3040411 | 0.79 | AURKB (0.53) | AURKBAURKAAURKCPLK4SRC | |
| SCHEMBL3037610 | 0.79 | AURKB (0.53) | AURKBAURKAAURKCPLK4SRC | |
| SCHEMBL13220890 | 0.79 | AURKB (0.55) | AURKBAURKAAURKCPLK4SRC | |
| SCHEMBL3037323 | 0.79 | MAPT (0.45) | AURKBAURKAAURKCSRCGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216765-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | claimed |
| US-8288536-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20100216765-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| US-7713973-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| EP-1812439-A2 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006044687-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060084650-A1 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084650-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | AURKB 122/4885AURKA 161/4885AURKC 56/4885 |
| US-20100216765-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | AURKB 122/4885AURKA 161/4885AURKC 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.